Inside informationEnglish
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 24/04/2026, 12:09
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 117789_20260424